The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine

Psychopharmacology

Volumn 119, Issue 2, 1995, Pages 222-230

  Fiorella, D ^a   Rabin, R A ^a   Winter, J C ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

5 HT2A; 5 HT2C; Antagonist correlation analysis; Drug induced stimulus control; m Chlorophenylpiperazine (mCPP); Serotonin (5 HT)

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1-(3-CHLOROPHENYL)PIPERAZINE; ANTIPARKINSON AGENT; ERGOLINE DERIVATIVE; MESULERGINE; PIPERAZINE DERIVATIVE; SEROTONIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; 1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXYLIC ACID 2 HYDROXY 1 METHYLPROPYL ESTER; KETANSERIN; METERGOLINE; PIRENPERONE; PIZOTIFEN; RISPERIDONE; RITANSERIN; SEROTONIN 1C RECEPTOR; SEROTONIN 2A RECEPTOR; SPIPERONE;

ANIMAL; ARTICLE; BINDING COMPETITION; DOSE RESPONSE; DRUG EFFECT; MALE; RAT; RAT STRAIN; ANIMAL EXPERIMENT; ANIMAL TISSUE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMAL; ANTIPARKINSON AGENTS; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOLINES; MALE; PIPERAZINES; RATS; RATS, INBRED F344; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028990260     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF02246164     Document Type: Article

References (49)

1. Asymmetrical cross-generalization in drug discrimination with lorazepam and pentobarbital training conditions
2. Different serotonin receptors mediate blood-pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats
3. Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamo-pituitary-adrenocortical axis in conscious rats
4. Perception of drug effects
5. Stimulus functions of drugs and the assessmet of abuse liability
6. (-)mCPP, a central 5-hydroxytrypatamine agonist, is a metabolite of trazadone
7. Plasma concentrations of trazadone and 1-(3-chlorophenyl)piperazine in man after a single oral dose of trazadone
8. Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP)
9. Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites
10. The effects of 5-HT and m-chlorophenylpiperazine (mCPP) on the efflux of [3H]5-HT from human perfused platelets
11. Serotonin function in anxiety II: Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects
12. Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine
13. Drug discrimination: methods of manipulation, measurement and analysis
14. Serotonin stimulated phosphoinositide turnover: mediation by the S2 binding site in rat cerebral cortex, but not subcortical regions
15. Agonist-induced phosphoinositide hydrolysis in rat choroid plexus
16. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic 5-HT1C and 5-HT2 receptors
17. Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites
18. Disposition and pharmacological effects of m-chlorophenylpiperazine in rats
19. The use of the drug discrimination paradigm for studying hallucinogenic agents
20. Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents
21. 1-(m-Chloro-phenyl)piperazine interactions with neurotransmitters in the human brain
22. The discriminative stimulus effects of clozapine in pigeons: involvement of 5-HT1C and 5-HT2 receptors
23. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to m-chlorophenylpiperazine in obsessive-compulsive disorder
24. Functional correlates of serotonin 5-HT1recognition sites
25. 5-HT1C receptor mediated stimulation of inositol phosphate production in pig choroid plexus
26. Competitive antagonism by recognized 5-HT2 receptor antagonists at 5-HT1C receptors in pig choroid plexus
27. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)
28. Analysis of the 5-HT1C receptor and the serotonin uptake site in Fawn-Hooded rat brain
29. The mCPP challenge test in schizophrenia: humoral and behavioral responses
30. Effects of chronic cocaine administration on the serotonergic system in rat brain
31. Molecular characterization of a functional cDNA encoding the serotonin1C receptor
32. m-Chlorophenylpiperazine as a probe of serotonin function
33. Behavioral indications for serotonin receptor hypersensitivity in panic disorder
34. The effect of 5-HT antagonists on m-chlorophenylpiperazine mediated responses
35. Behavioral hypersensitivity to m-chlorophenylpiperazine in a subject with subclinical panic attacks
36. Evidence that mCPP may have behavioral effects mediated by central 5-HT1C receptors
37. Potencies of antagonists indicate that 5-HT1C receptors mediate 1-3(chlorophenyl)piperazine induced hypophagia
38. m-Chlorophenylpiperazine effects in neuroleptic free schizophrenic patients
39. Effect of 1-(m-chlorophenyl) piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity
40. Serotoninselective arylpiperazines with neuroendocrine, temperature, and cardiovascular effects in humans
41. Characteristics of central 5-HT receptors and their adaptive changes following intracerebral 5,7-dihydroxytryptamine administration in the rat
42. Structure and functional expression of the cloned rat serotonin 5-HT1C receptors in choroid plexus
43. Putative selective 5-HT2antagonists block serotonin 5-HT1C receptors in choroid plexus
44. LSD and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to PI hydrolysis
45. The concept of selectivity in 5-HT research
46. Drug-induced stimulus control
47. Discriminative stimulus properties of m-chloropiperazine
48. Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls